# US 11,898,147 B2 · CpG-oligodeoxynucleotide compounds in combination with immune modulators for cancer immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,898,147 B2
- Document ID: US11898147B2
- Status: Granted
- Kind: B2
- Application number: 17/467,390
- Filed: 2021-09-06
- Published: 2023-03-09
- Granted: 2024-02-13
- Earliest claimed: 2021-09-06
- Assignees: National Health Research Institutes
- Applicants: National Health Research Institutes
- Inventors: Tsung-Hsien Chuang; Jen-Chih Tseng; Jing-Xing Yang; Yi-Ling Liu
- Web page: https://patentgrep.com/patent/US11898147B2

## CPC

- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 39/39541: {against normal tissues, cells}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/17: Immunomodulatory nucleic acids
- C12N 2310/315: Phosphorothioates
- C12N 2320/31: Combination therapy
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention discloses a combinational therapy for enhancing efficacy of immune checkpoint blockade for tumors with immune suppressive microenvironment. More specifically, this combination therapy involves the treatment of cancer through immune checkpoint inhibitors and CpG-oligodeoxynucleotides.

## Claims

### Claim 1

A pharmaceutical composition for treating cancer, comprising an immune checkpoint blockade and an adjuvant composition; wherein the adjuvant composition comprises at least one CpG-oligodeoxynucleotide; wherein the CpG-oligodeoxynucleotide is CpG-2722 (SEQ ID NO:5), the immune checkpoint blockade is an anti-PD1 antibody.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cancer possesses resistance to immunotherapy.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cancer is selected from the group consisting of melanoma, non-small cell lung cancer, renal cell carcinoma, hodgkin lymphoma, head and neck cancer, urothelial carcinoma, hepatocellular carcinoma, and small cell lung cancer.